Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor
A Phase 1, Open-Label, Parallel Group Study to Determine the Pharmacokinetics, Safety and Tolerability of Rucaparib in Patients With an Advanced Solid Tumor and Either Moderate Hepatic Impairment or Normal Hepatic Function
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Biała Podlaska, Poland, 21-500
- Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej
-
Poznań, Poland, 60-693
- Med Polonia Sp. z o.o.
-
Szczecin, Poland, 71-730
- Zachodniopomorskie Centrum Onkologii w Szczecinie
-
Warszawa, Poland, 02-681
- BioVirtus Centrum Medyczne
-
-
-
-
-
Bratislava, Slovakia, 831 01
- Summit Clinical Research s.r.o.
-
-
-
-
-
Newcastle Upon Tyne, United Kingdom, NE7 7DN
- Northern Centre for Cancer Care
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
All Patients:
- Patients ≥18 years of age at the time the ICF is signed;
- Patients with a histologically or cytologically confirmed advanced solid tumor who, in the opinion of the Investigator, could potentially benefit from treatment with rucaparib
- ECOG PS less than or equal to 2
- Adequate bone marrow and renal function
Hepatically Impaired Patients (in addition):
- Stable hepatic impairment as judged by the Investigator
- Moderate Hepatic Impairment (NCI-ODWG criteria) during Screening
Patients with Normal Hepatic Function (in addition):
• Normal Hepatic Function (NCI-ODWG criteria)
Exclusion Criteria:
All Patients:
- Prior treatment with chemotherapy, radiation, antibody therapy or other immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or investigational drugs within 14 days prior to day 1
- Ongoing toxicity ≥ Grade 2 per Common Terminology Criteria for Adverse Events criteria (CTCAE version 4.03)
- Prior treatment with any poly adenosine diphosphate ribose polymerase inhibitor
- Arterial or venous thrombi (including cerebrovascular accident), myocardial infarction, admission for unstable angina, cardiac angioplasty, stenting or poorly controlled hypertension within the last 3 months prior to Screening
- Pre-existing duodenal stent, and/or any gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib
- Hospitalization for bowel obstruction within 3 months prior to Day 1
- Untreated or symptomatic central nervous system (CNS) metastases
- Evidence or history of bleeding disorder
- Acute illness within 14 days prior to Day 1
- Active second malignancy
Hepatically Impaired Patients (in addition):
- Severe hepatic encephalopathy (Grade >2);
- History of liver transplantation;
- Advanced ascites or ascites that require drainage and albumin supplementation, as judged by the Investigator;
- Acute damage of the liver with Grade 4 AST/ALT values
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: no name
Group 1: patients with normal hepatic function Group 2: patients who have moderate hepatic impairment
|
In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144).
In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum plasma rucaparib concentration (Cmax)
Time Frame: day 1 to day 7
|
PK parameter of rucaparib to be calculated from the plasma concentration-time data
|
day 1 to day 7
|
|
Area under the plasma rucaparib concentration-time curve from time zero up to the last time point with quantifiable concentration (AUC0-last)
Time Frame: day 1 to day 7
|
PK parameter of rucaparib to be calculated from the plasma concentration-time data
|
day 1 to day 7
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area under the plasma rucaparib concentration-time curve from time zero up to time infinity (AUC0-inf)
Time Frame: day 1 to day 7
|
PK parameter of rucaparib to be calculated from the plasma concentration-time data
|
day 1 to day 7
|
|
Terminal half-life (t1/2) of rucaparib
Time Frame: day 1 to day 7
|
PK parameter of rucaparib to be calculated from the plasma concentration-time data
|
day 1 to day 7
|
|
Time to attain maximum plasma rucaparib concentration (Tmax)
Time Frame: day 1 to day 7
|
PK parameter of rucaparib to be calculated from the plasma concentration-time data
|
day 1 to day 7
|
|
Apparent clearance (CL/F) of rucaparib
Time Frame: day 1 to day 7
|
PK parameter of rucaparib to be calculated from the plasma concentration-time data
|
day 1 to day 7
|
|
Apparent volume of distribution during terminal phase (Vz/F) of rucaparib
Time Frame: day 1 to day 7
|
PK parameter of rucaparib to be calculated from the plasma concentration-time data
|
day 1 to day 7
|
|
Trough plasma concentration of rucaparib at steady state (Cmin,ss)
Time Frame: approximately 4 months
|
PK parameter of rucaparib to be calculated from the plasma concentration-time data
|
approximately 4 months
|
|
Renal clearance (CLR) of rucaparib
Time Frame: day 1 to day 2
|
PK parameter of rucaparib to be calculated from the plasma and urine concentration-time data
|
day 1 to day 2
|
|
Cumulative amount of rucaparib excreted in urine during urine collection period post rucaparib dose
Time Frame: day 1 to day 2
|
PK parameter of rucaparib to be calculated based on urine concentration-time data
|
day 1 to day 2
|
|
Fraction of administered rucaparib excreted into urine (Fe/F) during urine collection period post rucaparib dose
Time Frame: day 1 to day 2
|
PK parameter of rucaparib to be calculated based on the amount of rucaparib recovered in urine
|
day 1 to day 2
|
|
Incidence of Adverse Events [Safety and Tolerability]
Time Frame: From Day 1 to last patient visit in Part II (approximately 2 years)
|
From Day 1 to last patient visit in Part II (approximately 2 years)
|
|
|
Incidence of clinical laboratory abnormalities [Safety and Tolerability]
Time Frame: From Day 1 to last patient visit in Part II (approximately 2 years)
|
From Day 1 to last patient visit in Part II (approximately 2 years)
|
|
|
Incidence of dose modifications [Safety and Tolerability]
Time Frame: From Day 1 to last patient visit in Part II (approximately 2 years)
|
From Day 1 to last patient visit in Part II (approximately 2 years)
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum plasma metabolite concentration (Cmax)
Time Frame: day 1 to day 7
|
PK parameter for rucaparib metabolite(s) to be calculated from plasma concentration-time data
|
day 1 to day 7
|
|
Area under the plasma metabolite concentration-time curve from time zero up to the last time point with quantifiable concentrations (AUC0-last)
Time Frame: day 1 to day 7
|
PK parameter for rucaparib metabolite(s) to be calculated from plasma concentration-time data
|
day 1 to day 7
|
|
Area under the plasma metabolite concentration-time curve from time zero up to time infinity (AUC0-inf)
Time Frame: day 1 to day 7
|
PK parameter for rucaparib metabolite(s) to be calculated from plasma concentration-time data
|
day 1 to day 7
|
|
Terminal half-life (t1/2) of metabolite
Time Frame: day 1 to day 7
|
PK parameter for rucaparib metabolite(s) to be calculated from plasma concentration-time data
|
day 1 to day 7
|
|
Time to attain maximum plasma metabolite concentration (Tmax)
Time Frame: day 1 to day 7
|
PK parameter for rucaparib metabolite(s) to be calculated from plasma concentration-time data
|
day 1 to day 7
|
|
Plasma trough concentration of metabolite(s) at steady state (Cmin,ss)
Time Frame: day 1 to day 7
|
PK parameter for rucaparib metabolite(s) to be calculated from plasma concentration-time data
|
day 1 to day 7
|
|
Renal clearance (CLR) of metabolite(s)
Time Frame: day 1 to day 2
|
PK parameters for rucaparib metabolite(s) to be calculated from plasma and urine concentration-time data
|
day 1 to day 2
|
|
Cumulative amount of rucaparib metabolite(s) excreted in urine during urine collection period post rucaparib dose
Time Frame: day 1 to day 2
|
PK parameter for rucaparib metabolite(s) to be calculated from urine concentration-time data
|
day 1 to day 2
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CO-338-078
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.